The data used for the paper is uploaded as a STATA file, as well as the STATA Code that generates all the results. We will also make the data publicly available at acla.amsterdam.

Background {#sec005}
==========

Empirical research is considered most valuable when it aims to answer a specific causal question \[[@pone.0234349.ref001]\], as is the case in a randomized clinical trial. Randomization has the objective to avoid potential bias in the estimation of causal treatment effects by ensuring that a participant's treatment status is independent from both observed and unobserved characteristics. If successful, randomization enables internal validity \[[@pone.0234349.ref002]\], such that differences between participants in a clinical trial assigned to different treatment arms can, apart from random error, be attributed to the treatment under investigation \[[@pone.0234349.ref003]\].

However, randomized clinical trials often deploy some form of restriction when assigning participants to treatment arms, for example blocking, stratification or minimization, as to improve the balance obtained on known confounders \[[@pone.0234349.ref004]\]. Such restrictions increase the risk of subversion whenever random allocation sequences are observed or can be--partially- predicted; introducing pathways for selection bias in a randomized trial \[[@pone.0234349.ref005]\]. From a causal inference perspective, simple randomization is then to be preferred to avoid introducing such bias; thereby sacrificing some level of precision (i.e. resulting from covariate imbalances).

Yet, even if initial randomization is successful, additional concerns regarding causal inference arise in the presence of missing data. Missing data problems can introduce subsequent--and severe- bias when analyzing data from randomized clinical trials and should thus be acknowledged empirically. Several dimensions of missing data exist, which differ considerably in terms of their potential for raising causal inference concerns. In this paper, we focus on these phenomena and consider missing data on either background characteristics, treatment status or outcomes.

For causal inference, it is important to empirically acknowledge the potential importance of missing data problems. These issues can introduce bias in subsequent data analyses, thereby undermining initial randomization. Several dimensions of missing data exist, which differ considerably in terms of potential causal inference concerns. We consider missing data on background characteristics, treatment status and outcomes.

Missing data on background characteristics can be addressed relatively easy, either by means of a missing indicator method or imputation, thereby rendering the sample of randomized participants complete. Given that background characteristics are independent from treatment status by virtue of randomization, the resulting causal inferences with respect to the average treatment effect are internally valid.

Missing data on treatment status occurs when participants discontinue, for whatever reason, the assigned treatment. When gathering data on outcomes for these participants is successful, the possibility to estimate an internally valid intent-to-treat effect is retained. This measure--in itself- is informative regarding treatment policy effects and provides a lower-bound estimate of the average treatment effect.

Missing data on outcomes is widespread in clinical trials \[[@pone.0234349.ref006]\]. If such attrition co-varies with (un)observed characteristics and treatment assignment, this compromise initial randomization and causal inferences drawn from clinical trials \[[@pone.0234349.ref007]\]. While attrition bias may thus render the results from a study non-informative, the problem of missing outcome data has received relatively little attention in the clinical trial literature \[[@pone.0234349.ref008]\]. Missing data is often inadequately addressed by means of simple fixes \[[@pone.0234349.ref009]\], but also more advanced methods such as multiple imputation (MI) can yield biases as big as, or even bigger than, the bias in simple complete cases analysis results \[[@pone.0234349.ref008]\].

Based on a widely established categorization of missing outcome data scenarios \[[@pone.0234349.ref010]\], this study proposes empirical strategies for each scenario in the context of a randomized clinical trial and by adopting a causal inference perspective. An empirical solution for obtaining an internally valid treatment effect estimate in the presence of missing data is provided for each scenario. In addition, the underlying identifying assumptions that apply are made explicit, together with the extent to which--and how- they can be verified empirically.

Three missing data scenarios are distinguished, and each imposes different assumptions with respect to characterizing the missing data generation process:

1.  Missing Completely At Random (MCAR)

2.  Missing At Random (MAR)

3.  Missing Not At Random (MNAR)

MCAR assumes that the occurrence of a missing outcome is a random event, unrelated to treatment assignment and--observed and unobserved- background characteristics. MAR assumes that observed background characteristics can account for the non-random nature of missing data. Finally, MNAR assumes that the occurrence of a missing outcome is a non-random event that can be structurally related to both observed and--importantly- unobserved background characteristics. From a causal inference perspective, each scenario entails different empirical strategies to test its underlying identifying assumptions and also to address missing data concerns.

Addressing selective attrition {#sec006}
------------------------------

This study argues that -from a causal inference perspective- it is most appropriate to assume that the missing outcome data generating process in a randomized clinical trial is MNAR. Both MCAR and MAR impose overly restrictive identifying assumptions that are crucial for claiming that the estimated effect is internally valid, yet often unrealistic and empirically unverifiable. In the case of MNAR, common empirical bounding approaches rely on exploring worst-case scenario bounds, often resulting in very wide, uninformative, treatment effect estimate intervals.

Therefore, this study proposes to use a new Random Forest Lee Bounds (RFLB) approach that can be used to estimate relatively tight average treatment effect intervals, when assuming MNAR. The potential of exploiting RFLB in the presence of selective attrition is demonstrated using data from a recent randomized clinical trial which established the treatment effect of virtual reality cognitive behavior therapy (VR CBT) in addressing acrophobia (Donker et al., 2019). We show how RFLB can considerably increase the statistical power of bias-corrected treatment effect estimates for randomized clinical trials facing non-random missing outcome data, by exploiting both continuous and discrete predictor variables for attrition.

Baseline model {#sec007}
==============

Assume a randomized clinical trial conducted with the objective to estimate the effect of treatment *T* on outcome *y*~*i*~ for individual *i* (with *i* = 1,...,*N*). The two potential outcomes for individual *i* can then be represented by: $$y_{i} = \left\{ \begin{matrix}
{y_{1i}\mspace{14mu} if\ T_{i} = 1} \\
{y_{0i}\mspace{14mu} if\ T_{i} = 0} \\
\end{matrix}, \right.$$ and the individual treatment effect for individual *i* as: $$y_{0i} + \left( {y_{1i} - y}_{0i} \right)T_{i}.$$

Individuals cannot be randomly assigned to the treatment and control group simultaneously, such that only one of both potential outcomes *y*~0*i*~ and *y*~1*i*~ is observed for each individual which prevents the estimation of the individual treatment effects \[[@pone.0234349.ref002]\]. This observation is referred to as the fundamental problem of causal inference. Yet, the average treatment effect for these individuals can be estimated empirically using ordinary least squares regression: $$y_{i} = \alpha + \beta \bullet T_{i} + \varepsilon_{i},$$ where *α* and *β* are the parameters to be estimated and where *ε* represents the classical error term, assumed to be identically and independently distributed (i.i.d) with mean zero (*E*(*ε*~*i*~) = 0). The estimated expected outcome for treated and non-treated individuals is *E*(*y*~*i*~\|*T* = 1) = *α*+*β* and *E*(*y*~*i*~\|*T* = 0) = *α*, respectively, yielding the difference between these expected outcomes, *β*, to represent an unbiased estimated average treatment effect. Performing an independent sample t-test would yield the same average treatment effect.

A more precise estimate of this treatment effect can be obtained empirically by including observed background characteristics that are related to *y*~*i*~ in [Eq 1](#pone.0234349.e003){ref-type="disp-formula"}: $$y_{i} = \alpha + \beta \bullet T_{i} + {\mathbf{X}_{\mathbf{i}}}^{\prime}\mathbf{\delta} + \varepsilon_{i}.$$

Vector **X** represents the vector of observed background characteristics and parameter vector ***δ*** are the associated model parameters to be estimated. The estimated treatment effect is unbiased in both Eqs [1](#pone.0234349.e003){ref-type="disp-formula"} and [2](#pone.0234349.e004){ref-type="disp-formula"}, but the inclusion of background characteristics that are significantly related with the outcome variable reduces the standard error of *β* and thus increases the statistical power of empirically detecting this treatment effect.

Results {#sec008}
=======

Missing completely at random (MCAR) {#sec009}
-----------------------------------

MCAR assumes that missing outcomes are unrelated with treatment status and *all* background characteristics, whether observed or unobserved. Let indicator variable *M*(issing) denote 1 when outcome *y*~*i*~ is missing, and 0 otherwise. This *conditional mean zero* (CMZ) assumption of MCAR then implies *E*(*ε*~*i*~\|*T*~*i*~,***X***~***i***~) = 0, meaning that both observed treatment *T*~*i*~ and background characteristics **X** are uncorrelated with the error term *ε*~*i*~.

Let *N*~*fs*~ and *N*~*os*~ be the number of observations for, respectively, the full sample and the sample of individuals for which an outcome is observed and let *N*~*os*~≤*N*~*fs*~. If the occurrence of missing outcomes is truly random, then *P(T\|M) = P(T)* and an unbiased estimator of the treatment effect can be obtained empirically by estimating either [Eq 1](#pone.0234349.e003){ref-type="disp-formula"} or--for precision reasons- [Eq 2](#pone.0234349.e004){ref-type="disp-formula"}.

The analysis can then be performed on the 'complete case' sample, also referred to as listwise deletion. A drawback of this procedure is that the use of the smaller sample *N*~*os*~ can severely reduce statistical power. More precisely, if the goal was to have 80% statistical power to empirically detect a treatment effect, this power reduction by using the smaller sample *N*~*os*~ is reflected by *θ*, for which holds (see [S1 Appendix](#pone.0234349.s001){ref-type="supplementary-material"} for a full derivation of *θ*): $$\theta = 2.8 \bullet \sqrt{\frac{N_{os}}{N_{fs}}} - 1.96.$$

A power of 80% is associated with a *θ*-value of 0.84 (i.e. *N*~*os*~ = *N*~*fs*~). [Eq 3](#pone.0234349.e005){ref-type="disp-formula"} illustrates that the statistical power is reduced by attrition as *N*~*os*~\<*N*~*fs*~. For example, when $\sqrt{\frac{N_{os}}{N_{fs}}} = 0.75$, this implies a value for *θ* of 0.14, yielding a power of 56% and--thus- a power reduction of 24 percentage points (see [S1 Appendix](#pone.0234349.s001){ref-type="supplementary-material"}).

Therefore, a-priori knowledge about the extent to which missing outcomes will occur should be used to make an educated guess on the full-sample size needed (*N*~*fs*~), as to retain the ability to perform a complete case analysis on the observed sample (*N*~*os*~) with 80% statistical power.

A more fundamental problem with *MCAR* is that the randomness assumption of missing outcomes (CMZ) cannot be demonstrated, but merely be assumed. Empirically, this assumption can only be partially validated by two different estimation strategies. The first strategy is to estimate a (logistic/probalistic) regression model and show that treatment status *T*~*i*~ cannot be predicted empirically by the set of observed background characteristics **X**: $$T_{i} = \alpha + {\mathbf{X}_{\mathbf{i}}}^{\prime}\mathbf{\delta} + \varepsilon_{i}.$$

Generally a logistic or probability model is estimated, given the dichotomous nature of the dependent variable. Yet, for the validation purpose of causal inference considered here a simple linear regression model is sufficient to estimate, as we are not interested in the interpretation of the estimation parameters. The observed background characteristics should not explain treatment status if the identifying assumption of *MCAR* holds and the estimated coefficients of vector ***δ*** should all be statistically insignificant and close to zero. A second estimation strategy is to estimate--and compare- Eqs [5](#pone.0234349.e008){ref-type="disp-formula"} and [6](#pone.0234349.e009){ref-type="disp-formula"}: $$y_{i} = \alpha + \beta \bullet T_{i} + \varepsilon_{i}.$$ $$y_{i} = \alpha + \beta \bullet T_{i} + {\mathbf{X}_{\mathbf{i}}}^{\prime}\mathbf{\delta} + \varepsilon_{i}.$$

The estimated parameter *β* in the [Eq 5](#pone.0234349.e008){ref-type="disp-formula"} provides the t-test or Wald-test estimator of the treatment effect. The inclusion of observed background characteristics in [Eq 6](#pone.0234349.e009){ref-type="disp-formula"} should not statistically significantly change the estimated treatment effect *β* if the MCAR assumption of CMZ holds. The logic is similar to that of the first estimation strategy: if it is assumed that *P(T\|M) = P(T)*, then *P(T\|M*, ***X****) = P(T)* must also hold. However, if missing outcomes are structurally related to relevant background characteristics, then the estimated treatment effect -or treatment assignment- will depend on whether these background characteristics are included or not.

A key insight from both strategies is that showing that *T*~*i*~ is independent from observable characteristics is sufficient to argue this will also hold for all unobserved characteristics. The estimated treatment effect *β* can properly be inferred causally if this identifying assumption holds, but this can thus merely be assumed and not demonstrated unequivocally.

Based on the above, it could be argued that the term missing completely at random is somewhat confusing. It suggests that missing outcomes are not problematic due to its random nature, yet it is precisely this random nature that cannot be proven. At best, one can show empirically that the estimated treatment effect is independent from observed characteristics and--then- to assume that this will also be the case for all unobserved characteristics.

Missing At Random (MAR) {#sec010}
-----------------------

Different from MCAR, MAR assumes that missing outcomes can actually be non-random in nature, such that the CMZ not hold and [Eq 5](#pone.0234349.e008){ref-type="disp-formula"} will yield a biased treatment effect estimate. Yet, with MAR it is assumed that the selective nature of missing outcomes can fully be accounted for by a set of observed background characteristics **X**. This implies that P*(T\|M*, ***X****) = P(T\|****X****)*, such that treatment status *T*~*i*~-once controlled for observed background characteristics- is unrelated to missing observation status. This identifying assumption is referred to as *conditional mean independence* (CMI) and implies *E*(*ε*~*i*~\|*T*~*i*~,***X***) =*E*(*ε*~*i*~\|***X***)≠0. This is unproblematic as long as we are only interested in inferring the causal effect of treatment *T*~*i*~ and not in the causal effect of background characteristics **X.** Conditional on X, *T*~*i*~ is as if randomly assigned, such that treatment *T*~*i*~ is uncorrelated with *ε*~*i*~, but **X** can be correlated with *ε*~*i*~. The CMI assumption then implies that *E*(*ε*~*i*~\|*T*~*i*~ = 1,***X***) = *E*(*ε*~*i*~\|*T*~*i*~ = 0,***X***), yielding *E*(*y*~*i*~\|*T* = 1,**X**)−*E*(*y*~*i*~\|*T* = 0, **X**) = *β* and thus that the treatment effect estimate from [Eq 6](#pone.0234349.e009){ref-type="disp-formula"} is unbiased.

Whereas *MAR* is different from *MCAR* in assuming *conditional* randomness with respect to the missing outcomes, the underlying identifying assumption necessary to argue that the estimated treatment effect is causal is similar for both scenarios. As with *MCAR*, the validity of the identifying assumption for MAR--conditional mean independence- cannot be demonstrated. The two estimation strategies outlined before with *MCAR* can again be pursued, but are this time performed to show (1) how the probability of The pivotal assumption underlying *MAR* is that the inclusion of the set of observed background characteristics **X** in [Eq 6](#pone.0234349.e009){ref-type="disp-formula"} is sufficient to also account for the potential effects of non-observed background characteristics on observed treatment status. This assumption is similar to situation described in *MCAR*, and--again- it is not possible to empirically validate this conditional mean independence assumption on non-observed background characteristics. In practical terms, this implies that *MCAR* and *MAR* are similar in the identifying assumptions made, with the notable exception that the inclusion of observed background characteristics in [Eq 5](#pone.0234349.e008){ref-type="disp-formula"} can alter the estimated treatment effect for *MAR*, while this is not allowed to be possible with *MCAR* (and are only included for precision).

The aforementioned observation that the estimated treatment effect is allowed to change with *MAR* due to the inclusion of ***X*** is what makes it distinctively different from *MCAR*. Whereas the estimation strategy in [Eq 5](#pone.0234349.e008){ref-type="disp-formula"} with *MCAR* serves to falsify its identifying assumption of missing outcomes as purely random events, it is used with *MAR* to empirically control for the non-random nature of missing outcomes. The identifying assumption for *MAR* that treatment status is then CMI on unobservables -after having included the observed characteristics **X-** is a strong assumption to make and empirically untractable.

Missing Not At Random (MNAR) {#sec011}
----------------------------

Given that randomness of missing outcomes cannot be demonstrated, a more appropriate point of departure is MNAR and to assume that missing outcomes *can* result from non-random events (Graham, 2009), such that the probability of observing a missing outcome can be structurally related to both observed and--importantly- unobserved characteristics. In contrast to MAR, MNAR thus implies that the inclusion of observed background characteristics **X** cannot control for the selective nature of missing values, rendering results thus obtained to be biased.

MNAR thus not assume CMZ or CMI, such that no unbiased point estimate for *β* can be generated using [Eq 5](#pone.0234349.e008){ref-type="disp-formula"} or [6](#pone.0234349.e009){ref-type="disp-formula"}. As such, additional assumptions regarding the potential selective nature of missing outcomes are required to estimate *β*. Empirically, this often implies performing a bounding procedure in which two contrasting scenarios regarding attrition (e.g. "worst"- and "best"-case) are considered; thereby yielding an interval estimate for *β* instead.

### Bounding procedures {#sec012}

Rather than correcting the point estimate of treatment effect *β* for potential bias, bounding procedures yield treatment effect interval estimates instead. In their seminal work on dealing with missing data in randomized experiments, Horowitz and Manski \[[@pone.0234349.ref011]\] first provide a general assumption-free framework, with the objective to deal with non-random missing outcomes in an experimental setting. Their approach places very conservative bounds around treatment effect estimates. Essentially, this approach implies determining the worst- and best-case scenario for the missing outcomes, based on the observed data. By replacing the missing outcomes with the worst- and best-case outcomes, a lower and upper bound is constructed for the estimated treatment effect *β*. While this approach provides an intuitive benchmark, a major disadvantage is that these conservative bounds in clinical trials suffering from sizable attrition can often turn out to be largely uninformative, as they tend to be very wide and (thus) often include zero. Yet, this bounds analysis approach is valuable in being among the first to (1) acknowledge the potential severity of the imposed bias on the point estimate due to missing outcome data, and (2) provides an intuitive solution for dealing with this uncertainty by focusing on bound estimates for *β*, rather than on a single point estimate.

By imposing a monotonicity assumption on the selection mechanism of missing outcomes, Lee \[[@pone.0234349.ref012]\] provided a -generally- more useful bounds procedure which generates relatively tighter bounds. This assumption entails that assignment to treatment can only affect the likelihood of attrition in one direction, such that there is no heterogeneous effect--in terms of sign- of treatment assignment on attrition.

Let *S*~*i*~ be a binary indicator, with *S*~*i*~ = 0 indicating that outcome *y*~*i*~ is not observed due to attrition. Furthermore, let 1(∙) be the indicator function which counts the number of observations satisfying status indicated between parenthesis. The proportion of outcomes observed for treatment (T = 1) and control (T = 0) group can then be written as: $$\begin{matrix}
{q_{T = 1} = \frac{\sum_{i}{1 \bullet \left( T_{i} = 1,S_{i} = 1 \right)}}{\left. {\sum_{i}{1 \bullet \left( T_{i} = 1 \right.}} \right)}} \\
{q_{T = 0} = \frac{\sum_{i}{1 \bullet \left( T_{i} = 0,S_{i} = 1 \right)}}{\left. {\sum_{i}{1 \bullet \left( T_{i} = 0 \right.}} \right)}.} \\
\end{matrix}$$

The bounds procedure first determines which group suffers less from attrition. In accordance with the empirical example presented later in this section, and without loss of generalization, we assume that *q*~*T*\ =\ 0~\>*q*~*T*\ =\ 1~. The Lee bounds procedure then trims the outcome distribution of the control group by removing $q = \frac{q_{T = 0} - q_{T = 1}}{q_{T = 0}}$ observations from the lower (upper) end of the distribution such that an upper (lower) bound for the treatment effect *β* is estimated. Intuitively, the *q*-value indicates the proportion of control observations that ought to be removed in order to achieve a similar attrition rate in both the control and treatment group.

If the monotonicity assumption of sample selection holds, the treatment effect bounds estimated apply to so-called *never-attriters*. These are participants for whom the outcome will be observed (*S*~*i*~ = 1), irrespective of being assigned to the treatment (T = 1) or control (T = 0) group. By virtue of randomization, the treatment control difference in means will then provide bias-corrected bounds estimates of the average treatment effect for this particular group of participants. This subpopulation can be characterized by the distribution of **X** for participants with non-missing outcome data in the assignment group that remains untrimmed (here: treatment). Also, when the trimming proportion is zero, there is a limited test of whether the monotonicity assumption holds for observables (Lee, 2009) by estimating [Eq 4](#pone.0234349.e007){ref-type="disp-formula"} on the subsample of participants selected in the bounding procedure and by verifying that treatment status *T*~*i*~ cannot be predicted by **X**. The monotonicity assumption is the only identifying assumption, and if violated the estimated lower and upper bound may provide biased bounds estimates for the never attriters.

### Empirical example {#sec013}

To showcase the Lee bounds procedure, the randomized clinical trial data from Donker et al. (2019) is utilized. The objective of this study was to estimate the treatment effect of ZeroPhobia---a virtual reality cognitive behavior therapy (VR CBT)--on acrophobia symptoms. In a single-blind randomized clinical trial, 193 participants were randomly assigned to the treatment (n = 96) and a wait-list control group (n = 97). To measure acrophobia the Acrophobia Questionnaire was used \[[@pone.0234349.ref013]\] and the mean (SD) AQ-Total outcome scores for the treatment and control group were 48.46 (24.33) and 74.68 (21.55), respectively.

For 11 (40) participants of the control (treatment) group, no outcome was observed. The attrition proportion is therefore largest for the wait-list control group, such that the $q = \frac{q_{T = 0} - q_{T = 1}}{q_{T = 0}} = \frac{\left( 86/97 \right) - \left( 56/96 \right)}{\left( 86/97 \right)} = 0.34$ (or 34 percent). To generate a lower and upper bound estimate for treatment effect *β*, the Lee bounds procedure then trims the outcome distribution of the wait-list control group by removing consecutively the 34 percent highest and lowest outcome values observed.

[Fig 1](#pone.0234349.g001){ref-type="fig"} visualizes the Lee bounds, when applied to the data of Donker et al. \[[@pone.0234349.ref014]\]. [Fig 1](#pone.0234349.g001){ref-type="fig"} shows three panels in which the blue line represents the untrimmed intervention distribution and the red line the distribution of the control group, which is either trimmed (i.e. the upper and lower panel) or untrimmed (i.e. the middle panel). The middle panel shows the treatment effect point estimate as a reduction in acrophobia symptoms with 26.22 points (i.e. 74.68--48.46), when potential attrition bias as a result of MNAR is not taken into account. The distributions associated with the lower bounds estimate display that the upper 34 percent of the control distribution is trimmed (removed), yielding a lower bound estimate of -22.33. Moreover, the confidence interval of this lower bound estimate indicates that the mean difference of the AQ post-score is significantly smaller than zero. This is an important empirical result, as it indicates that even the most conservative Lee bound estimate indicates that ZeroPhobia significantly reduced acrophobia symptoms. The upper bound estimate of -47.50 points is obtained by trimming the lower 34 percent of the control distribution. The Lee bound results thus indicate that the estimated treatment effect is arguably somewhere between this interval of -22.33 and -47.50 points. When the confidence intervals for the point estimates of both bounds are also taken into consideration, the corresponding interval estimate for the average treatment effect is \[-13.43; -56.90\].

![Lee bounds trimming procedure.](pone.0234349.g001){#pone.0234349.g001}

The Lee bound procedure can also be performed conditionally on discrete background characteristic variables, with the objective to further tighten the bounds thus obtained. This conditioned approach essentially implies that the trimming is performed separately for each category as defined by the discrete variable(s). In order to illustrate this 'tightening by conditioning'- effect, suppose that only gender is used as the conditioning variable and that attrition occurs solely among female participants. In the unconditional bounding procedure, all extreme values of the control group outcome distribution are trimmed, regardless gender. In the conditional version, however, extreme observations of male participants in the control group are not trimmed (i.e. only extreme observations of women are). If we would trim only the 34 percent for women in the control group, then the conditional and unconditional Lee bounds are similar only if these trimmed female observations are all located at the extremes of the distribution. If this is not the case, the bounds will be relatively tight, as the resulting lower and the upper bound estimates will be closer around the initial point estimate of *β*.

Random forest lee bounds {#sec014}
------------------------

When assuming MNAR and estimating corresponding bounds for the average treatment effect, a limitation of the aforementioned conditioning procedure with Lee bounds is that it requires discrete groups to perform the trimming procedure. As such, the set of background characteristics that can be used to tighten the bounds is restricted to include only non-continuous variables. Thus, if attrition can to a large extend be explained by continuous variables, this information can unfortunately not be optimally exploited by the Lee bounds procedure. Therefore, we propose a Random Forest Lee Bounds (RFLB) approach, such that also continuous variables can be used for obtaining tighter bounds around the estimate for treatment effect *β*.

The RFLB procedure first classifies data points efficiently into the attrition class they belong to. For this, a decision tree is used together with an entropy (*E*) function. The entropy function measures the purity of the data and -in the context of attrition- this indicates the proportion of attrition. The decision tree is used to partition data recursively into two groups such as to maximize data purity. This recursive data-splitting process can be explained using [Fig 2](#pone.0234349.g002){ref-type="fig"}, under the simplifying assumption that the observed input vector **X** consists of only two background characteristics, *x*~*1*~ and *x*~*2*~ (this example is taken from Plak et al. \[[@pone.0234349.ref015]\]). The red dots in the figure represent *{x*~*1*~, *x*~*2*~} observations for missing outcomes, while the green dots represent non-missing outcome observations. In this example, the first algorithmic split occurred at x~2~ ≥ a~2~, implying that the two data samples obtained by this split are more pure than the initial data sample. The second, third and fourth split occurred at x~1~ ≥ a~4~, x~1~ ≥ a~1~, and x~2~ ≥ a~3,~ respectively.

![Decision tree data splitting.\
This is a revised figure, taken from Zou & Schonlau \[[@pone.0234349.ref017]\].](pone.0234349.g002){#pone.0234349.g002}

The algorithm stops when splitting the data does not yield more purified data samples and avoids further reduction of degrees of freedom for the adjusted residual sum of squares. We note that the random forest approach can be applied using multiple conditioning variables and is suitable for both categorical classification problems (such as shown in [Fig 2](#pone.0234349.g002){ref-type="fig"}), and continuous prediction problems. The example explained above can also be represented as a continuous outcome problem for which the random forest approach builds regression trees instead of classification trees and indicates--in our case---which characteristics best explain the observed variation in attrition.

The random forest approach avoids over-fitting by applying k-fold cross-validation and takes into account that small changes in the data can yield large changes in the final tree obtained, by selecting the splitting variable at each step from *m* out of *x* randomly drawn input variables \[[@pone.0234349.ref016]\].

The Random Forest Lee Bounds (RFLB) procedure presented here can be summarized in four steps. First, a random forest is estimated using a set of background characteristics. Second, an importance graph is created which indicates how effective each characteristic reduces the variance (i.e. increases the prediction performance of the model). A random benchmark variable is included as covariate in the model, such that it can be evaluated if a covariate is more important than a random benchmark variable and--thus- whether it should be used to tighten the bounds. Third, a decision tree is estimated with only those variables included that were marked as important by the importance graph in the previous step. Fourth, discrete group indicator variables are generated using the decision tree from the previous step and used as conditioning variables in the Lee bounds procedure.

To reiterate, the rationale for using the random forest approach is to ensure that also continuous variables can be optimally exploited in the bounding procedure, and not to optimize the out-of-sample predictive power of the model. The obtained bounds will be tighter if these continuous variables statistically explain attrition. To see whether this is the case, random forest lee bounds are estimated applying the aforementioned procedure and using the ZeroPhobia randomized clinical trial data. The importance graph presented by [Fig 3](#pone.0234349.g003){ref-type="fig"} indicates that the treatment indicator variable explains most of the attrition variation. This variable therefore receives an importance value of 1 and all other variables receive a value relative to that of the most important variable. The random variable receives a value of .3 and--importantly- all other variables (i.e, gender, age and AQ pre-scores) are considered less important in explaining variance than this random variable. This implies that the association between attrition and the variables gender, age and AQ pre-scores is not statistically significant and explains why Donker et al. \[[@pone.0234349.ref014]\] perform an unconditional Lee bounds procedure. Yet, if the covariation between attrition and treatment assignment is indeed associated with some background characteristics, then the bounds can be tightened by conditioning on these variables.

![Importance graph attrition variation.](pone.0234349.g003){#pone.0234349.g003}

To illustrate that additional conditioning on a continuous variable can further tighten the bounds, attrition is simulated in the data from Donker et al. \[[@pone.0234349.ref014]\], such that the selective nature of the simulated attrition is now associated jointly with treatment status, gender and pre-score, while leaving the average treatment effect estimate unaffected. The simulation method is outlined in more detail in [S2 Appendix](#pone.0234349.s002){ref-type="supplementary-material"}. [Fig 4](#pone.0234349.g004){ref-type="fig"} shows the importance graph and illustrates that the attrition is selective and conditional on the simulated characteristics gender and pre-scores.

![Importance graph simulated attrition.\
The relative importance of the intervention variable is excluded from the figure, as only background characteristics are to be considered for tightening Random Forest Lee Bounds.](pone.0234349.g004){#pone.0234349.g004}

That attrition is selective with respect to gender and pre-score is a necessary but not sufficient condition for the bounds to be tightened by RFLB. It is only sufficient when the covariance between attrition and treatment assignment is conditional on these background characteristics as well. [Fig 5](#pone.0234349.g005){ref-type="fig"} shows that these interaction terms are indeed important, which is why the variables Female and AQ pre-scores are selected for conditioning.

![Importance graph simulated attrition interaction terms.](pone.0234349.g005){#pone.0234349.g005}

[Table 1](#pone.0234349.t001){ref-type="table"} summarizes the various bounding estimates obtained when performing unconditional Lee bounds, conditional Lee bounds and the RFLB introduced here. Columns 2 and 3 show the estimated lower and upper bound. Columns 4 and 5 show the 95% confidence intervals, which can be considered a more appropriate comparison between the different bounding approaches, as this also acknowledges precision loss resulting from the reduction of degrees of freedom when conditioning on background characteristics.

10.1371/journal.pone.0234349.t001

###### Bounding estimation results.

![](pone.0234349.t001){#pone.0234349.t001g}

                             Estimated Treatment Effect                                     
  -------------------------- ---------------------------- ------------------------ -------- --------
  Unconditional Lee- bound   -37.33                       -17.89                   -39.86   -15.44
                             ***Width***: *19*.*44*       ***Width***: *24*.*42*            
  Conditional Lee bound      -37.70                       -19.85                   -40.15   -17.49
  (Female)                   ***Width***: *17*.*85*       ***Width***: *22*.*66*            
  Random forest Lee bound    -32.65                       -20.39                   -35.86   -17.94
  (Female, Pre-scores)       ***Width***:*12*.*26*        ***Width***:*17*.*92*             

The estimation results of [Table 1](#pone.0234349.t001){ref-type="table"} show that the intervals are most tight when RFLB is performed. The 95% confidence intervals indicate that--relative to unconditional Lee bounds- the reduction in interval width is 7.2% with conditional Lee bounds, and 26.6% with RFLB. It follows that RFLB is the preferred bounding approach, as it provides the most precise bias-corrected interval estimate for the average treatment effect of ZeroPhobia.

To generalize the bounding estimation results we also performed simulations in which the bounding estimates were again obtained under different treatment sizes: small, medium and large (i.e. *d* = 0.2, *d* = 0.4 and *d* = 0.8). These bounding results are shown in [Table 2](#pone.0234349.t002){ref-type="table"} and the results suggest that the unconditional Lee bounds are tightened by the RFLB approach with 19.8, 16.8 and 16.6 percent for respectively a small, medium and large treatment size. This is an important result: when the effect size becomes smaller it is more likely that 0 lies and thus more important to obtain tighter bounds.

10.1371/journal.pone.0234349.t002

###### Bounding estimation results for small, medium and large effect sizes.

![](pone.0234349.t002){#pone.0234349.t002g}

                                                                                         95% conf. interval                    
  ------------------------------------------------- ---------- -------- ------- -------- -------------------- -------- ------- --------
  **Unconditional Lee Bound**                                                                                                  
  Small (d = 0.2)                                   -0.280     -0.162   0.118   .        -0.297               -0.145   0.153   .
  Medium (d = 0.4)                                  -0.560     -0.325   0.235   .        -0.595               -0.289   0.306   .
  Large (d = 0.8)                                   -1.119     -0.650   0.470   .        -1.189               -0.578   0.610   .
  **Conditional Lee Bound** (Female)                                                                                           
  Small (d = 0.2)                                   -0.281     -0.164   0.117   0.825    -0.298               -0.147   0.152   0.655
  Medium (d = 0.4)                                  -0.557     -0.326   0.231   1.836    -0.591               -0.291   0.300   1.768
  Large (d = 0.8)                                   -1.123     -0.644   0.479   -1.961   -1.193               -0.573   0.620   -1.540
  **Random Forest Lee Bound** (Female, Pre-score)                                                                              
  Small (d = 0.2)                                   \--0.269   -0.175   0.094   19.818   -0.287               -0.155   0.132   13.294
  Medium (d = 0.4)                                  -0.533     -0.338   0.196   16.802   -0.570               -0.297   0.272   10.933
  Large (d = 0.8)                                   -1.069     -0.677   0.392   16.609   -1.142               -0.597   0.545   10.665

More generally, it holds that RFLB will always produce interval widths that are smaller or similar compared to the other bounding approaches *if* the importance graph indicates that the interaction terms explain a significantly amount of the in attrition. This result is intuitive, since both conditional bounding approaches ensure that similar or less extreme values of the observed outcome distributions are trimmed, resulting tighter interval estimates. Moreover, the imposed assumptions by RLFB are equivalent to the Lee bounds procedure, but RFLB allows for conditioning on continuous variables, which is crucial for precision gains in randomized clinical trials as the pre-treatment scores is--often- the best predictor of the outcome observed at end point.

Discussion {#sec015}
==========

This study proposes to use a new Random Forest Lee Bounds (RFLB) approach that can be applied to estimate relatively tight average treatment effect intervals, while allowing for non-random missing outcome data (MNAR). An appealing feature of the RFLB procedure is that it allows for tightening intervals by exploiting the observed associations of attrition with both categorical *and* continuous background characteristics, as has been demonstrated empirically in this study.

In the case of a randomized clinical trial, the internal validity of RFLB entails an additional identifying monotonicity assumption. In the case of randomized clinical trials, this implies that if--for example- assignment to treatment induces some participants to drop out, it cannot simultaneously cause other participants to *no*t drop out. If this assumption holds, RFLB results are internally valid for the subpopulation of *non-attriters*.

Missing outcome data are unavoidable in randomized clinical trials and arguably depend on non-random unobserved data \[[@pone.0234349.ref018]\]. Bounding approaches serve to accommodate such selective attrition processes and to acknowledge the resulting uncertainty with respect to causal inference. Yet, the potential of bounding procedures for generating informative--relatively precise- interval estimates for the average treatment effect depends crucially on the ability to statistically predict attrition using pre-treatment characteristics.

Conclusion {#sec016}
==========

The importance of randomization in clinical trials has long been acknowledged for avoiding selection bias and enabling internal validity of the research results reported. Yet, many clinical trials suffer from attrition between randomization and follow-up data collection, such that attrition bias reintroduces concerns with respect to causal inference. This study takes a causal inference perspective when addressing distinct scenarios of missing outcome data (MCAR, MAR and MNAR) and provides an overview of empirical strategies that can be applied to estimate the average treatment effect, improve precision of the estimator, and to test whether the underlying identifying assumptions hold.

While many studies assume MCAR or MAR, the corresponding identifying assumptions are very restrictive, often untenable \[[@pone.0234349.ref018]\], and can hardly be verified empirically using the observed data. It is therefore appropriate to allow missing outcome data in clinical trials to be the result of non-random unobserved events (i.e. MNAR) and to address this issue accordingly. Yet, existing empirical approaches for dealing with MNAR rely on exploring worst-case scenario bounds and often result in very wide, uninformative, treatment effect estimate intervals.

By exploiting information from all observed background characteristics, the RFLB procedure proposed in this paper can considerably increase the statistical power of bias-corrected treatment effect estimates for randomized clinical trials facing non-random missing outcome data. As such, RFLB can hopefully facilitate researchers -whether involved in clinical trials or other disciplines- in allowing for post-assignment attrition to be non-random in nature and in addressing this accordingly.

Supporting information {#sec017}
======================

###### 

(DOCX)

###### 

Click here for additional data file.

###### 

(DOCX)

###### 

Click here for additional data file.

###### 

(DTA)

###### 

Click here for additional data file.

###### 

(DO)

###### 

Click here for additional data file.

10.1371/journal.pone.0234349.r001

Decision Letter 0

Berger

Vance

Academic Editor

© 2020 Vance Berger

2020

Vance Berger

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1 May 2020

PONE-D-20-02997

Addressing Missing Data in Randomized Clinical Trials: A Causal Inference Perspective

PLOS ONE

Dear PhD van Klaveren,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

I agree with the reviewers, and would say minor revision.  But I do have one other comment to add.  Specifically, this statement here:

In other words, randomization enables internal validity (Rubin, 1974), such that

differences between participants in a clinical trial assigned to different treatment arms can,

apart from random error, be attributed to the treatment under investigation (Jüni, Altman &

Egger, 2001).

This claim is categorically untrue.  The reason for it being false should be discussed, as opposed to just deleting it, since this is a common sentiment, and needs to be refuted.  It is somewhat disgraceful that authors are still making this claim even today, when we know better.  I would refer the authors to my book:

Berger, VW (2005). "Selection Bias and Covariate Imbalances in Randomized Clinical Trials", John Wiley & Sons, Chichester.

==============================

We would appreciate receiving your revised manuscript by Jun 15 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Vance Berger

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Additional Editor Comments (if provided):

I do have one other comment to add. Specifically, this statement here:

In other words, randomization enables internal validity (Rubin, 1974), such that

differences between participants in a clinical trial assigned to different treatment arms can,

apart from random error, be attributed to the treatment under investigation (Jüni, Altman &

Egger, 2001).

This claim is categorically untrue. The reason for it being false should be discussed, as opposed to just deleting it, since this is a common sentiment, and needs to be refuted. It is somewhat disgraceful that authors are still making this claim even today, when we know better. I would refer the authors to my book:

Berger, VW (2005). "Selection Bias and Covariate Imbalances in Randomized Clinical Trials", John Wiley & Sons, Chichester.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The paper addresses an important topic - missing data and related causal inference in RCTS.

The paper is well-written but could be improved further with more relevance to readers with the inclusion of (1) simulations with different baseline covariate distributions under different treatment effect sizes: small, medium and large and (2) relevant data and syntax to enable replication of authors findings.

Reviewer \#2: The manuscript by Cornelisz et al. takes a causes inference approach to address selection bias and missingness in outcomes due to MCAR, MAR, and MNAR in clinical trials. To do this, the authors provide causal inference-based strategies for estimating the average treatment effect, improve precision, and to test some underlying assumptions related to missingness.

The article was well written and easy to follow.

See below for my comments.

\\\\begin{enumerate}

\\\\item On page 10, change \"demonstrate\" to \"demonstrated\" in the sentence \"The potential of exploiting RFLB\...\".

\\\\item On page 11, the sentence \"Individuals are randomly assigned to one of both treatment conditions, such that always only one of both potential outcomes\....\" seems a little confusing. Can the authors clarify this sentence?

\\\\item On page 15, the sentence \"The term \'missing at random\' therefore does not defines missing outcomes as random events\" also needs to be clarified. Can the authors double check this sentence?

\\\\item On page 17, can the authors say more about the monotonicity assumption since the assumption of the bounding procedure depends on this. What happens when the monotonicity assumption is violated?

\\\\item Are there certain assumptions/conditions that need to be met in order to apply the RFLB - this was not clear. Can you say more about the assumptions?

\\\\end{enumerate}

\\\\end{document}

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0234349.r002

Author response to Decision Letter 0

21 May 2020

We have responded to the reviewers and the editor in the uploaded documents (cover letter and reviewer comments). We note that we did not used track changes, but presented this text and the placement also in the uploaded reply.

###### 

Submitted filename: Reply to Reviewer 1.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0234349.r003

Decision Letter 1

Berger

Vance

Academic Editor

© 2020 Vance Berger

2020

Vance Berger

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

26 May 2020

Addressing Missing Data in Randomized Clinical Trials: A Causal Inference Perspective

PONE-D-20-02997R1

Dear Dr. van Klaveren,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Vance Berger

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

10.1371/journal.pone.0234349.r004

Acceptance letter

Berger

Vance

Academic Editor

© 2020 Vance Berger

2020

Vance Berger

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

5 Jun 2020

PONE-D-20-02997R1

Addressing Missing Data in Randomized Clinical Trials: A Causal Inference Perspective

Dear Dr. van Klaveren:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Vance Berger

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
